Next Article in Journal
Bucket-Handle Meniscal Tears Might Not Be an Urgency: The Time to Meniscus Repair Does Not Seem to Affect the Mid-Term Outcome—A Retrospective Study of Sixty Tears with a Mean Follow-Up of 6 Years
Previous Article in Journal
Greater Risk of Periprosthetic Joint Infection Associated with Prolonged Operative Time in Primary Total Knee Arthroplasty: Meta-Analysis of 427,361 Patients
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Adherence to Screening Tests for Gynaecological and Colorectal Cancer in Patients with Diabetes in Spain: A Population-Based Study (2014–2020)

by
Luyi Zeng-Zhang
1,
Javier de Miguel-Diez
2,
Ana López-de-Andrés
3,*,
Rodrigo Jiménez-García
3,
Zichen Ji
2,
Olalla Meizoso-Pita
1,
Cristina Sevillano-Collantes
1 and
Jose J. Zamorano-León
3
1
Endocrinology and Nutrition Department, Infanta Leonor University Hospital, Universidad Complutense de Madrid, 28031 Madrid, Spain
2
Respiratory Care Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
3
Department of Public Health and Maternal & Child Health, Faculty of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(11), 3047; https://doi.org/10.3390/jcm13113047
Submission received: 17 April 2024 / Revised: 18 May 2024 / Accepted: 21 May 2024 / Published: 22 May 2024
(This article belongs to the Section Endocrinology & Metabolism)

Abstract

:
Objectives: Both diabetes mellitus (DM) and gynaecological and colorectal cancers are highly prevalent diseases. Furthermore, the presence of DM constitutes a risk factor and poor prognostic indicator for these types of cancer. This study is based on the European Health Interview Surveys in Spain (EHISS) of 2014 and 2020. It aimed to determine the trends in adherence to screening tests for gynaecological cancers (breast and cervical) and colorectal cancer, compare adherence levels between populations with and without diabetes, and identify predictors of adherence in the population with diabetes. Methods: An epidemiological case-control study based on the EHISS data of 2014 and 2020 was conducted. The characteristics of participants who underwent screening tests were analysed based on the presence or absence of DM, and predictors of adherence to these preventive activities were identified. Results: A total of 1852 participants with reported DM and 1852 controls without DM, adjusted for age and sex, were included. A higher adherence to mammography was observed in women without diabetes compared to those with diabetes, although statistical significance was not reached (72.9% vs. 68.6%, p = 0.068). Similarly, higher Pap smear adherence was observed in the population without diabetes in the age group between 60 and 69 years compared to the population with diabetes (54.0% vs. 45.8%, p = 0.016). Pap smear adherence among women with diabetes was significantly higher in the EHISS of 2020 (52.0% in 2014 vs. 61.0% in 2020, p = 0.010), as was the case for faecal occult blood testing (13.8% in 2014 vs. 33.8% in 2020, p < 0.001), but it was not significant for mammography (70.4% in 2014 vs. 66.8% in 2020, p = 0.301). Overall, the predictors of adherence to screening tests were older age, history of cancer and higher education level. Conclusions: Adherence levels to cancer screening tests were lower in the population with diabetes compared to those without diabetes, although an improvement in Pap smear and faecal occult blood test adherence was observed in 2020 compared to 2014. Understanding predictors is important to improve adherence rates in the population with diabetes.

1. Introduction

Diabetes mellitus (DM) is among the most prevalent chronic diseases in the Spanish population, with its prevalence doubling in recent years from 7.6% to 14.8%, positioning Spain as the country with the second-highest prevalence in Europe [1]. It is associated with the presence of multiple comorbidities, including various types of cancer [2]. Specifically, an estimated 1.2- to 1.5-fold increase in the relative risk of developing breast and colorectal cancer (CRC) has been observed in patients with type 2 DM, alongside an increased risk of cervical cancer in those with type 1 DM. Hyperglycaemia, hyperinsulinism and the association with obesity have been postulated as possible pathogenic mechanisms whose role in the development of gynaecological and CRC is widely known [3,4].
In Spain, cancer remains a leading cause of mortality, with a reported incidence of 279,260 new cases in 2023. Of these, 42,721 were CRC, 35,001 were breast cancer and 2326 were cervical cancer [5].
To facilitate early detection of the most prevalent cancers, various screening programmes for breast, cervical and CRC have been progressively implemented in Spain since 1990 [6]. Mammography is used for breast cancer screening in women aged 50 to 69 years, and from 40 years onward for those with risk factors, with screenings scheduled every two years [7]. Cervical cancer screening targets women aged 25 to 64 years through cervical cytology, also known as the Papanicolaou (Pap) smear, conducted every three years. Since 2019, human papillomavirus testing has been incorporated into cervical cancer screening [8,9]. Lastly, CRC screening involves faecal occult blood testing (FOBT) for individuals over 50 years old, recommended biennially [9].
These oncological screening systems have been recognised as effective tools for secondary prevention, enhancing disease prognosis [10,11]. European guidelines stipulate that at least 45% of the target population should undergo CRC screening, and 70% should undergo gynaecological cancer screening, to observe significant beneficial effects at the population level [12,13]. However, previous studies have noted a declining trend in the utilisation of breast and cervical cancer screening programmes among women with DM over the past decades, despite their heightened risk of gynaecological cancers [14].
Therefore, this study aimed to ascertain the temporal trend in adherence to screening tests for gynaecological and CRC based on the European Health Interview Surveys in Spain (EHISS) from 2014 to 2020. It also sought to compare adherence levels between populations with and without diabetes and identify healthcare, sociodemographic and lifestyle variables predictive of adherence to oncological screening programmes among individuals with diabetes.

2. Materials and Methods

2.1. Design

An observational, retrospective, case-control epidemiological study was conducted using data from the EHISS for 2014 and 2020. In Spain, the EHISS was conducted by the National Statistics Institute under the coordination and supervision of the Ministry of Health. This programme involved personal interviews with a representative sample of the non-institutionalised population aged 15 or older residing in Spain. Participants were selected through multistage probability sampling, with primary-stage units being census sections and secondary-stage units being main family households.
Surveys conducted in 2014 were in-person, whereas those in 2020 were initially in-person until March, then transitioned to telephone interviews due to the impact of the COVID-19 pandemic.
The methodology employed for the EHISS has remained consistent across different editions, enabling the comparison of results obtained in different years, and is detailed by the Spanish National Statistics Institute [15].

2.2. Selection of Cases and Controls

All participants reporting a medical diagnosis of DM were classified as cases. Individuals were categorised as cases if they answered affirmatively to the question: “Has a doctor ever diagnosed you with diabetes?” Participants reporting no DM were considered controls. One control was randomly assigned for each case, considering the edition of the EHISS in which they participated, as well as sex, age and place of residence.

2.3. Variables

Three dependent variables were selected. The first, mammography as a preventive practice, was assessed by asking participants whether they had undergone a mammogram in the previous two years. The age interval considered suitable for mammography was 40 years or older. The second variable, Pap smear usage, was evaluated by asking participants whether they had undergone a Pap smear in the previous three years. Women aged 18 to 69 years were considered eligible for Pap smear. Lastly, adherence to CRC screening was determined by whether individuals had undergone FOBT in the past two years, with individuals not adhering classified as non-adherents. Both men and women aged 50 to 69 years were considered eligible for FOBT. All variables were derived from questions included in the EHISS, and data were thus self-reported by participants.
The independent variables were:
  • Demographic and clinical characteristics: sex, age, education level, living with a partner, self-rated health and body mass index (BMI).
  • Concomitant diseases: chronic obstructive pulmonary disease (COPD), cardiac ischemia, stroke, cancer, mental illness and high blood pressure (HBP).
  • Risk habits: alcohol consumption, active smoking and sedentary lifestyle.
Detailed descriptions and categories of these variables are presented in Table S1.

2.4. Endpoints

The primary endpoints of this study are the following:
  • To establish the temporal trends in adherence to gynecological cancer screening tests and CRC screening tests across the Spanish population using data from the EHISS for the period 2014 to 2020. We will measure adherence as the proportion of the targeted population that completed the recommended screening tests during the aforementioned timeframe.
  • To compare the adherence rates to these screening tests between individuals with and without diabetes. This analysis will involve calculating the percentage of individuals in each group who have undergone the recommended screenings within the prescribed intervals.
  • To identify the key healthcare, sociodemographic and lifestyle predictors of adherence to oncological screening programs among individuals with diabetes. For this, we will perform multivariate logistic regression analyses to determine which factors significantly influence adherence rates, incorporating all independent variables of demographic and clinical characteristics, concomitant diseases and risk habits.

2.5. Statistical Analysis

The distribution of the sample of women undergoing breast and cervical cancer screening, as well as men and women undergoing FOBT, was described. All quantitative variables had a normal distribution and were expressed as mean and standard deviation (SD). Qualitative variables were represented as frequency and percentage.
For the comparisons made, quantitative variables were studied using analysis of variance or Student’s t-test, and qualitative variables were analysed using the chi-square test. Adherence to the three tests was analysed based on the independent variables of the study, according to the presence or absence of diabetes.
Multivariable analyses were performed using logistic regression; three models were generated based on the absence or presence of diabetes for each oncological screening programme. These models allowed us to evaluate the adjusted change from 2014 to 2020 and predictors of adherence to breast, cervical and CRC screening programmes. The models included variables with a significant association in bivariate analysis or those reported as relevant in the literature.
The level of statistical significance was set at p < 0.05 for all comparisons. All statistical analysis was conducted using SPSS version 26.0.

2.6. Ethical Considerations

EHISS data are freely accessible and available on the official website of the Ministry of Health of Spain. Because these are anonymised data, according to Spanish legislation, approval by an ethics committee was not required to conduct this study.

3. Results

3.1. Characteristics of Population with Diabetes According to EHISS Surveys to Assess Adherence to Oncological Screening Programmes

Table 1 depicts the distribution of demographic characteristics, comorbidities, risk habits and performance of screening tests among cases based on the year of EHISS completion. This study included 1852 cases diagnosed with DM and 1852 age-, sex-, EHISS edition- and residence-matched controls. Among the cases, 941 participants (50.8%) were from the 2014 EHISS and 911 (49.2%) belonged to the 2020 EHISS. Of the 2014 EHISS cases, 531 (56.4%) were male and for the 2020 EHISS, this figure was 521 (57.2%), with no significant differences observed. The mean age of cases from the 2014 and 2020 EHISS was also similar at 57.7 years (SD 9.7) and 58.4 years (SD 9.1), respectively (Table 1).
The predominant education level was secondary education, with 707 participants (75.1%) in the 2014 EHISS and 694 (76.2%) in the 2020 EHISS, showing a different distribution of primary and university education between the two surveys. More than half of the cases lived with a partner, specifically, 622 (66.1%) in the 2014 EHISS and 571 (62.7%) in the 2020 EHISS. Most participants perceived their health status as good or very good, specifically, 544 (57.8%) in the 2014 EHISS and 482 (52.9%) in the 2020 EHISS, significantly higher in the 2014 EHISS. The most frequent comorbidity was HBP, with 511 participants (54.3%) in the 2014 EHISS and 485 (53.2%) in the 2020 EHISS. Significant differences were also observed in BMI distribution, with more obesity among individuals with diabetes in 2014 (Table 1).
Regarding the performance of screening tests, no significant differences were observed in the breast cancer programme: 266 women (70.4%) in 2014 and 244 (66.8%) in 2020 reported having undergone mammography in the two years preceding the survey. However, the Pap smear adherence rate among women with diabetes was significantly higher in 2020 (52.0% in 2014 vs. 61.0% in 2020, p = 0.010). Conversely, a significant increase was seen in individuals with diabetes reporting having undergone FOBT in the two years before the 2020 survey compared to the 2014 survey (13.8% in 2014 vs. 33.8% in 2020, p < 0.001). This increase in FOBT adherence in 2020 was observed in both sexes (Table 1).

3.2. Comparison of Mammography Adherence Rates between Women with and without Diabetes according to Sociodemographic, Health and Lifestyle Variables

Table 2 displays the comparison of characteristics of participants who reported undergoing mammography based on the presence or absence of DM. The results revealed higher adherence among women without diabetes, although the difference was not statistically significant. Moreover, greater adherence was observed in women without diabetes who perceived their health status as good or very good, compared to women with diabetes (72.3% vs. 70.3%, p = 0.031). In this regard, a higher proportion of adherence to mammography was found in women without diabetes who reported no cardiac ischemia (73.3% vs. 68.3%, p = 0.041), cancer (72.2% vs. 66.9%, p = 0.035), HBP (71.7% vs. 63.3%, p = 0.009), or overweight or obesity (BMI < 25 kg/m2; 72.6% vs. 60.6%, p = 0.006) compared to women with diabetes. Similarly, women without diabetes with active smoking habits showed greater adherence to mammography compared to women with diabetes (74.5% vs. 62.5%, p = 0.026).
Variables such as age, living with a partner and alcohol consumption were associated with mammography adherence in the group of women without diabetes, whereas age, cancer diagnosis and HBP were significantly associated with undergoing mammography in women with diabetes. For the total population, age, living with a partner, cancer diagnosis and HBP were associated with adherence to breast cancer screening.

3.3. Comparison of Pap Smear Adherence Rates between Women with and without Diabetes according to Sociodemographic, Health and Lifestyle Variables

Table 3 presents the data comparing the characteristics of patients who reported undergoing Pap smears, depending on the presence or absence of DM. A higher adherence was observed in the population without diabetes in the age group between 60 and 69 years compared to the population with diabetes (54.0% vs. 45.8%, p = 0.016). Regarding comorbidities, a higher percentage of women without diabetes undergoing Pap smears reported no COPD (61.8% vs. 56.4%, p = 0.041), no cancer (68.4% vs. 49.3%, p = 0.031) and no HBP (60.0% vs. 49.6%, p = 0.015) compared to the population with diabetes. Conversely, for those reporting mental illness, the highest adherence percentage was observed among women with diabetes (61.2% vs. 56.2%, p = 0.005).
Variables such as age, education level, self-rated health, diagnosis of cardiac ischemia, stroke, alcohol consumption, sedentary lifestyle and BMI were associated with Pap smear adherence in the women without diabetes group, whereas variables such as age, education level, diagnosis of HBP, sedentary lifestyle, BMI and survey year were significantly associated with undergoing Pap smear testing in women with diabetes. For the total population, age, education level, living with a partner, self-rated health, diagnosis of cardiac ischemia, history of stroke and HBP, alcohol consumption, active smoking, sedentary lifestyle, BMI and survey year were associated with adherence to cervical cancer screening.

3.4. Comparison of Adherence Rates to FOBT between Individuals with and without Diabetes according to Sociodemographic, Health and Lifestyle Variables

Table 4 presents the comparison of characteristics among participants aged over 50 years who reported undergoing FOBT based on the positive or negative diagnosis of DM. Significant differences in adherence between populations with and without diabetes were observed concerning only education level, showing a higher adherence percentage among individuals with diabetes with a lower education level compared to those without diabetes (19.0% vs. 9.6%, p = 0.017).
Variables such as age, education level, diagnosis of stroke or cancer, alcohol consumption, active smoking, sedentary lifestyle and survey year were associated with FOBT adherence in the population without diabetes, whereas variables such as living with a partner, sedentary lifestyle and survey year were significantly associated with undergoing FOBT in the population with diabetes. For the total population, age, education level, living with a partner, cancer diagnosis, sedentary lifestyle and survey year were associated with adherence to CRC screening.

3.5. Predictors of Adherence to Breast Cancer Screening Programme Based on Diabetes Diagnosis

Table 5 displays the predictors of adherence to mammography among female participants based on the presence or absence of diabetes and in the total study population. In women without diabetes, age over 50 years, living with a partner and alcohol consumption were significantly associated with better adherence to mammography. In women with diabetes, age over 50 years and a history of cancer were associated with higher adherence to this diagnostic test. In the total participant cohort, age over 50 years, living with a partner and cancer diagnosis were associated with better adherence to mammography. Conversely, the presence of DM was associated with lower adherence to this screening procedure.

3.6. Predictors of Adherence to Cervical Cancer Screening Programmes Based on Diabetes Diagnosis

Table 6 presents the predictors of Pap smear adherence among female participants based on the presence or absence of diabetes and in both populations. In participants without diabetes, only having a secondary or higher education level was associated with better Pap smear adherence. In participants with diabetes, both having a secondary or higher education level and participating in the 2020 EHISS were associated with higher Pap smear adherence. In the overall female participant cohort, the same associations as in participants with diabetes were observed. However, a sedentary lifestyle was identified as a predictor of poorer adherence to undergoing this screening test. Diabetes was not associated with adherence after multivariable adjustment.

3.7. Predictors of Adherence to CRC Screening Programme Based on Diabetes Diagnosis

Table 7 compiles the predictors of adherence to FOBT among participants aged over 50 years based on the presence or absence of diabetes and in both populations. In individuals without diabetes, age over 60 years, secondary or higher education level, a history of cancer and participation in the 2020 EHISS group were predictors of better adherence to FOBT. However, a sedentary lifestyle was identified as a predictor of poorer adherence to this diagnostic test. In individuals with diabetes, only participation in the 2020 EHISS was a predictor of better adherence to FOBT. In the total participant cohort aged over 50 years, age over 60 years, secondary education level, a history of cancer and participation in the 2020 EHISS were associated with better adherence to FOBT. However, a sedentary lifestyle was associated with poorer adherence to undergoing this screening test.

4. Discussion

We analysed the temporal trend of adherence rates to breast, cervical and CRC screening programmes among individuals with diabetes residing in Spain, based on data from the EHISS surveys conducted in 2014 and 2020. The results revealed lower adherence to the studied oncological screening programmes among the population with diabetes compared to those without diabetes, with a significant increase in adherence to preventive Pap smear and FOBT tests among patients with diabetes from 2014 to 2020.
The results regarding adherence to preventive cervical cancer screening showed a 9% significant increase from 52.0% in 2014 to 61.0% in 2020 among women with diabetes aged 18 to 69 years. Additionally, adherence to FOBT rose by 20% in 2020 compared to 2014 among the population with diabetes. This increase suggests a shift in trend regarding adherence to cervical and CRC screening programmes compared to previous years. Previous studies have reported stable and lower adherence levels over time among the Spanish population with diabetes for both screening programmes [14,16]. Concerning mammography, the findings did not show significant differences between 2014 and 2020 among women with diabetes. However, notably, our study found a significant decrease in adherence to gynaecological screening programmes among individuals with diabetes compared to those without diabetes. Previous studies have also shown lower adherence to breast and cervical cancer screening programmes among individuals with diabetes compared to those without diabetes [14,17,18,19,20,21]. Similarly, prior studies have identified reduced adherence to FOBT among the population with diabetes compared to those without diabetes [17,18,19]. However, our study did not observe this difference, consistent with another prior study conducted in Spain [16].
A possible reason for the lower adherence to oncological screening programmes among people with diabetes could be that disease control might compete with preventive care, with patients focusing on clinical diabetes control and perceiving long-term disease prevention as less important, even though they may be related to diabetes [22,23]. Different studies have described that physicians and patients tend to prioritise demands and only deal with the most pressing or symptomatic problems, leading to clinical inertia [14,20].
Among the adults with diabetes in our study, several factors associated with higher adherence to the oncological screenings analysed were found in both populations, with and without diabetes. Age was identified as a predictor of mammography in both groups, with and without diabetes. Consistent with other studies, adherence to mammography increased with age up to 69 years [24,25,26]. Additionally, living with a partner was a positive factor for mammography adherence in women without diabetes. This finding coincides with previous studies, suggesting that women living with a partner may be more motivated by their family members to undergo preventive tests [24,25].
Surprisingly, moderate alcohol consumption was associated with higher adherence to breast cancer screening. This result may seem controversial; however, in Spain, moderate alcohol consumption is common among women of higher socioeconomic status, and higher socioeconomic status is associated with greater acceptance of cancer screening tests. Regarding women with diabetes, the only factor in addition to age that seemed to affect adherence to mammography was, interestingly, cancer diagnosis. Previous studies have also established a positive relationship between higher comorbidity and adherence to breast cancer screening in women with diabetes [16].
In previous studies, more mammograms were performed in the population with diabetes [27]. However, in our study, the presence of diabetes was identified as a predictor of poorer adherence to mammography, as previously described in a study conducted in Spain in 2009 [20]. Understanding the factors influencing adherence to mammography in patients with diabetes is important because this population has a higher risk of breast cancer [28] and a higher risk of mortality exists in women with diabetes with breast cancer compared to those without diabetes [29].
As expected, a higher level of education was positively associated with adherence to cervical cancer screening in both populations, with and without diabetes. This finding is consistent with other studies [30]. Higher education level and socioeconomic status have been associated with greater use of preventive services and cancer screening rates, especially in the case of cervical cancer, whose screening is based on an opportunistic system [25]. In the group of women with diabetes, the survey edition was identified as a positive predictor, suggesting that, albeit insufficiently, women with diabetes seemed to progressively adhere to Pap smears.
In both groups, with and without diabetes, education level was a predictor of CRC screening adherence. Among the analysed parameters, age, education level, cancer diagnosis and sedentary lifestyle were predictors of adherence to CRC screening in individuals without diabetes. In line with the programmes previously described, a previous diagnosis of cancer and a sense of greater vulnerability to CRC risk could explain higher adherence in subjects aged 60–69 years [31,32]. Regarding the finding that a higher education level was associated with greater adherence in people without diabetes, other authors have reported similar results [33,34], suggesting that knowing the signs or symptoms of CRC is associated with the use of procedures for this type of cancer and staying current with screening [35,36]. Interestingly, healthy behaviours such as an active lifestyle may reflect individual perceptions of the importance of overall good health, prevention of health risks and perceived risk [37,38]. This reasoning could explain our results regarding the negative association of sedentary behaviour with CRC screening. Finally, in both groups, with and without diabetes, the edition of EHISS was a predictor. The progressive improvement in adherence levels to FOBT over time seems to reflect its gradual implementation since 2000 in Spain, with the programme being introduced at different times in each region [9]. In this sense, our group previously identified that the different periods of CRC screening implementation constituted a crucial factor in improving adherence to CRC screening from 2011 to 2017 in the resident population in Spain [39].
Obesity, a large number of chronic diseases and even mental disorders are highly prevalent in the population with diabetes. Interestingly, previous studies have reported that obesity and mental disorders may contribute to the decreased uptake described in the population with diabetes in the present study. Indeed, patients with obesity may face physician bias, which may in turn lead to poor patient–physician relationships and communication and lower rates of screening [40,41]. Furthermore, patients’ self-perceptions of negative body image may affect preferences for screening; factors such as embarrassment and even unwanted advice to lose weight may be considered barriers that affect participation [42]. Conversely, it has been suggested that own hospital attendance due to diabetes or concomitant chronic diseases may be a potential barrier to preventive care. In this regard, providing guideline-adherent chronic disease care also requires more consultation time than physicians have available per patient [43,44,45,46], which may lead to the prioritisation of diabetes-related care over routine preventive care [45,46,47].
As a reflection of these results, a need exists for educational programmes targeting the population with diabetes and healthcare professionals to raise awareness of the importance of undergoing the described preventive services. We propose that primary care professionals actively engage in querying patients with diabetes about their participation in screening tests and provide reminders to those who have not yet completed such assessments. Additionally, interventions that allow increasing acceptance of screening should be studied and implemented, including electronic reminders and active recruitment strategies, such as follow-up phone calls or a second invitation letter.
With the aim of increasing adherence to oncologic screening programs in the population with diabetes, it is also important to point out that shared care between primary care physicians and diabetes specialists has been associated with better adherence to diabetes-related health services and a higher likelihood of receiving breast and cervical cancer screening compared with care by either practitioner alone [48]. Accordingly, this suggests that integrated diabetes management models may therefore improve attention to other recommended preventive health services by offloading diabetes care from primary care physicians. Supporting diabetes self-management as well as emphasising the importance of preventive care in the diabetic population through training courses or communication media may also better screening participation.
Our study has significant strengths. Firstly, the large sample size provides high power to detect small significant statistical differences. Secondly, it included a control group for a more rigorous study. Thirdly, being a nationally representative survey, the sample is representative of the Spanish population. Fourthly, the methodological rigour of the EHISS ensures the validity of the study and allows for the comparison of these data in future studies with the next editions of the same survey. However, our study also has limitations. The most important is that it did not distinguish between type 1 and type 2 diabetes. The pathophysiology of the two types of diabetes is different, so the result obtained jointly may not be fully applicable when dealing with one of the two specific types. Similarly, the survey does not specify the level of diabetes control, or the treatments employed, factors that could influence both quality of life and adherence to screening tests. The data obtained in the surveys also correspond to information reported by the participants and thus may not fully correspond to their clinical situation due to memory biases or socially conditioned responses, which could influence the results and affect the validity of the study. In addition, although most participants completed the survey in person, a portion of the 2020 survey was conducted by telephone due to the COVID-19 pandemic, and the survey did not distinguish the method of contact with the participant. This fact may lead to certain biases derived from this difference. Due to the large sample size and the high number of comparisons made, the type I error may not be negligible. Therefore, caution must be exercised when interpreting the results of this study. Additionally, despite identifying several predictor factors associated with adherence to screening tests, given that this is an observational study, there is a need for caution in interpreting these associations as causal. Finally, due to the standard methodology used for conducting the surveys, there is a lack of relevant data for analysing adherence to screening tests, such as diet, socioeconomic level and psychological barriers.

5. Conclusions

The adherence levels to the oncological screening systems implemented in Spain were significantly lower in the population with diabetes compared to the population without diabetes. However, an improvement in Pap smear and FOBT adherence was observed in the 2020 survey compared to the 2014 survey among the population with diabetes, although the figures were still far from desirable adherence levels. A better understanding of adherence predictors is important to improve the rate of screening tests in patients with diabetes, given their higher risk of developing these types of cancer, their lower adherence to the screening tests and their worse prognosis.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm13113047/s1, Table S1: Definition of variables according to the questions included in the European Health Interview Surveys in Spain conducted in the years 2014 and 2020.

Author Contributions

Conceptualization, L.Z.-Z., J.J.Z.-L., J.d.M.-D. and R.J.-G.; methodology, A.L.-d.-A.; validation, O.M.-P. and C.S.-C.; formal analysis, Z.J.; funding, A.L.-d.-A. and R.J.-G.; writing—original draft, L.Z.-Z., J.J.Z.-L., J.d.M.-D. and R.J.-G.; writing—review and editing, A.L.-d.-A., Z.J., O.M.-P. and C.S.-C. All authors have read and agreed to the published version of the manuscript.

Funding

This work has been supported by the Madrid Government (Comunidad de Madrid-Spain) under the Multiannual Agreement with Universidad Complutense de Madrid under the Excellence Programme for university teaching staff, in the context of the V PRICIT (Regional Programme of Research and Technological Innovation). It was also supported by Universidad Complutense de Madrid, Grupo de Investigación en Epidemiología de las Enfermedades Crónicas de Alta Prevalencia en España (970970).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The anonymised EHISS datasets are freely accessible and can be downloaded by anyone on the Ministry of Health’s website. https://www.sanidad.gob.es/estadEstudios/estadisticas/EncuestaEuropea/home.htm (accessed on 8 October 2023). All other relevant data are included in the paper.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.N.; Mbanya, J.C.; et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022, 18, 109119. [Google Scholar] [CrossRef] [PubMed]
  2. Teck, J. Diabetes-Associated Comorbidities. Prim. Care 2022, 49, 275–286. [Google Scholar] [CrossRef] [PubMed]
  3. Vrachnis, N.; Iavazzo, C.; Iliodromiti, Z.; Sifakis, S.; Alexandrou, A.; Siristatidis, C.; Grigoriadis, C.; Botsis, D.; Creatsas, G. Diabetes mellitus and gynecologic cancer: Molecular mechanisms, epidemiological, clinical and prognostic perspectives. Arch. Gynecol. Obstet. 2016, 293, 239–246. [Google Scholar] [CrossRef]
  4. Gallagher, E.J.; Le Roith, D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol. Rev. 2015, 95, 727–748. [Google Scholar] [CrossRef] [PubMed]
  5. Estimates of the Incidence of Cancer in Spain, 2023. Red Española de Registros de Cáncer. Available online: https://redecan.org/storage/documents/02d62122-9adb-4d35-b6d0-551435dbe4ae.pdf (accessed on 15 April 2024).
  6. Luengo-Matos, S.; Polo-Santos, M.; Saz-Parkinson, Z. Mammography use and factors associated with its use after the introduction of breast cancer screening programmes in Spain. Eur. J. Cancer Prev. 2006, 15, 242–248. [Google Scholar] [CrossRef] [PubMed]
  7. García-Gutiérrez, S.; Orive, M.; Sarasqueta, C.; Legarreta, M.J.; González, N.; Redondo, M.; Rivero, A.; Serrano-Aguilar, P.; Castells, X.; Quintana, J.M.; et al. Health services research in patients with breast cancer (CAMISS-prospective): Study protocol for an observational prospective study. BMC Cancer 2018, 18, 54. [Google Scholar] [CrossRef] [PubMed]
  8. Perkins, R.B.; Guido, R.S.; Castle, P.E.; Chelmow, D.; Einstein, M.H.; Garcia, F.; Huh, W.K.; Kim, J.J.; Moscicki, A.B.; Nayar, R.; et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J. Low Genit. Tract. Dis. 2020, 24, 102–131. [Google Scholar] [CrossRef] [PubMed]
  9. Ascunce, N.; Salas, D.; Zubizarreta, R.; Almazán, R.; Ibáñez, J.; Ederra, M. Network of Spanish Cancer Screening Programmes (Red de Programas Espanoles de Cribado de Cancer). Cancer screening in Spain. Ann. Oncol. 2010, 21 (Suppl. S3), iii43–iii51. [Google Scholar] [CrossRef] [PubMed]
  10. US Preventive Services Task Force (USPSTF). Available online: https://www.uspreventiveservicestaskforce.org/uspstf/ (accessed on 15 April 2024).
  11. Council Recommendation of 2 December on Cancer Screening. Off. J. Eur. Union 2003. Available online: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:327:0034:0038:EN:PDF (accessed on 15 April 2024).
  12. European Colorectal Cancer Screening Guidelines Working Group; von Karsa, L.; Patnick, J.; Segnan, N.; Atkin, W.; Halloran, S.; Lansdorp-Vogelaar, I.; Malila, N.; Minozzi, S.; Moss, S.; et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full supplement publication. Endoscopy 2013, 45, 51–59. [Google Scholar] [CrossRef]
  13. Perry, N.M.; Allgood, P.C.; Milner, S.E.; Mokbel, K.; Duffy, S.W. Mammographic breast density by area of residence: Possible evidence of higher density in urban areas. Curr. Med. Res. Opin. 2008, 24, 365–368. [Google Scholar] [CrossRef]
  14. Martinez-Huedo, M.A.; Lopez de Andres, A.; Hernandez-Barrera, V.; Carrasco-Garrido, P.; Martinez Hernandez, D.; Jiménez-Garcia, R. Adherence to breast and cervical cancer screening in Spanish women with diabetes: Associated factors and trend between 2006 and 2010. Diabetes Metab. 2012, 38, 142–148. [Google Scholar] [CrossRef] [PubMed]
  15. Instituto Nacional de Estadística. Encuesta Europea de Salud en España 2020. Metodología. Available online: https://www.sanidad.gob.es/estadEstudios/estadisticas/EncuestaEuropea/EncuestaEuropea2020/Metodologia_EESE_2020.pdf (accessed on 15 April 2024).
  16. Jimenez-Trujillo, I.; Jiménez-García, R.; Esteban-Hernández, J.; Hernández-Barrera, V.; Carrasco Garrido, P.; Salinero-Fort, M.A.; Cardenas-Valladolid, J.; López-de-Andrés, A. Predictors of Adherence to Multiple Clinical Preventive Recommendations among Adults with Diabetes in Spain. PLoS ONE 2015, 10, e0131844. [Google Scholar] [CrossRef] [PubMed]
  17. McBean, A.M.; Yu, X. The underuse of screening services among elderly women with diabetes. Diabetes Care 2007, 30, 1466–1472. [Google Scholar] [CrossRef] [PubMed]
  18. Karathanasi, I.; Kamposioras, K.; Cortinovis, I.; Karampoiki, V.; Alevizaki, P.; Dambrosio, M.; Zorba, E.; Panou, C.; Pantazi, E.; Bristianou, M.; et al. Moving ahead in diabetics’ cancer screening; food for thought from the Hellenic experience. Eur. J. Cancer Care 2009, 18, 255–263. [Google Scholar] [CrossRef] [PubMed]
  19. Lipscombe, L.L.; Hux, J.E.; Booth, G.L. Reduced screening mammography among women with diabetes. Arch. Intern. Med. 2005, 165, 2090–2095. [Google Scholar] [CrossRef] [PubMed]
  20. Jiménez-Garcia, R.; Hernandez-Barrera, V.; Carrasco-Garrido, P.; Gil, A. Prevalence and predictors of breast and cervical cancer screening among Spanish women with diabetes. Diabetes Care 2009, 32, 1470–1472. [Google Scholar] [CrossRef]
  21. Jiménez-García, R.; Rodríguez-Rieiro, C.; Hernandez-Barrera, V.; Carrasco Garrido, P.; López de Andres, A.; Esteban-Vasallo, M.D.; Domínguez-Berjón, M.F.; Astray-Mochales, J. Negative trends from 2008/9 to 2011/12 seasons in influenza vaccination coverages among high risk subjects and health care workers in Spain. Vaccine 2014, 32, 350–354. [Google Scholar] [CrossRef] [PubMed]
  22. Zhao, G.; Ford, E.S.; Ahluwalia, I.B.; Li, C.; Mokdad, A.H. Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes. J. Gen. Intern. Med. 2009, 24, 270–275. [Google Scholar] [CrossRef] [PubMed]
  23. Owens, M.D.; Beckles, G.L.; Ho, K.K.; Gorrell, P.; Brady, J.; Kaftarian, J.S. Women with diagnosed diabetes across the life stages: Underuse of recommended preventive care services. J. Womens Health 2008, 17, 1415–1423. [Google Scholar] [CrossRef]
  24. Ricardo-Rodrigues, I.; Jiménez-García, R.; Hernández-Barrera, V.; Carrasco-Garrido, P.; Jiménez-Trujillo, I.; López de Andrés, A. Social disparities in access to breast and cervical cancer screening by women living in Spain. Public Health 2015, 129, 881–888. [Google Scholar] [CrossRef]
  25. Cabeza, E.; Esteva, M.; Pujol, A.; Thomas, V.; Sánchez-Contador, C. Social disparities in breast and cervical cancer preventive practices. Eur. J. Cancer Prev. 2007, 16, 372–379. [Google Scholar] [CrossRef] [PubMed]
  26. Roland, K.B.; Benard, V.B.; Soman, A.; Breen, N.; Kepka, D.; Saraiya, M. Cervical cancer screening among young adult women in the United States. Cancer Epidemiol. Biomark. Prev. 2013, 22, 580–588. [Google Scholar] [CrossRef] [PubMed]
  27. Tabaei, B.P.; Herman, W.H.; Jabarin, A.F.; Kim, C. Does diabetes care compete with the provision of women’s preventive care services? Diabetes Care 2005, 28, 2644–2649. [Google Scholar] [CrossRef] [PubMed]
  28. Larsson, S.C.; Mantzoros, C.S.; Wolk, A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int. J. Cancer 2007, 121, 856–862. [Google Scholar] [CrossRef] [PubMed]
  29. Peairs, K.S.; Barone, B.B.; Snyder, C.F.; Yeh, H.C.; Stein, K.B.; Derr, R.L.; Brancati, F.L.; Wolff, A.C. Diabetes mellitus and breast cancer outcomes: A systematic review and meta-analysis. J. Clin. Oncol. 2011, 29, 40–46. [Google Scholar] [CrossRef] [PubMed]
  30. Momeni, R.; Hosseini, Z.; Aghamolaei, T.; Ghanbarnejad, A. Determinants factors to Pap smear screening among married women in a city of South Iran: Applying the BASNEF model. BMC Womens Health 2020, 20, 237. [Google Scholar] [CrossRef]
  31. Cossu, G.; Saba, L.; Minerba, L.; Mascalchi, M. Colorectal Cancer Screening: The Role of Psychological, Social and Background Factors in Decision-making Process. Clin. Pract. Epidemiol. Ment. Health 2018, 14, 63–69. [Google Scholar] [CrossRef] [PubMed]
  32. Mema, S.C.; Yang, H.; Vaska, M.; Elnitsky, S.; Jiang, Z. Integrated Cancer Screening Performance Indicators: A Systematic Review. PLoS ONE 2016, 11, e0161187. [Google Scholar] [CrossRef] [PubMed]
  33. Tang, T.S.; Solomon, L.J.; McCracken, L.M. Barriers to fecal occult blood testing and sigmoidoscopy among older Chinese-American women. Cancer Pract. 2001, 9, 277–282. [Google Scholar] [CrossRef]
  34. Millar, M.M.; Edwards, S.L.; Herget, K.A.; Orlean, S.B.; Ofori-Atta, B.S.; Kirchhoff, A.C.; Carter, M.E.; Nagata, M.; Sweeney, C. Adherence to Guideline-Recommended cancer screening among Utah cancer survivors. Cancer Med. 2023, 12, 3543–3554. [Google Scholar] [CrossRef]
  35. Gimeno-García, A.Z.; Quintero, E.; Nicolás-Pérez, D.; Parra-Blanco, A.; Jiménez, A. Colorectal cancer screening in a Spanish population. Med. Clin. 2009, 133, 736–740. [Google Scholar] [CrossRef]
  36. Gimeno-García, A.Z.; Quintero, E.; Nicolás-Pérez, D.; Jiménez-Sosa, A. Public awareness of colorectal cancer and screening in a Spanish population. Public Health 2011, 125, 609–615. [Google Scholar] [CrossRef]
  37. Martín-López, R.; Hernández-Barrera, V.; De Andres, A.L.; Garrido, P.C.; De Miguel, A.G.; García, R.J. Breast and cervical cancer screening in Spain and predictors of adherence. Eur. J. Cancer Prev. 2010, 19, 239–245. [Google Scholar] [CrossRef]
  38. İdiz, C.; Çakır, Ç.; Keğin, M.; Ulusoy, A.İ. Assessment of colorectal cancer awareness in patients admitted to the General Surgery outpatient clinic. Eur. Res. J. 2021, 7, 93–99. [Google Scholar] [CrossRef]
  39. Zamorano-Leon, J.J.; López-de-Andres, A.; Álvarez-González, A.; Maestre-Miquel, C.; Astasio-Arbiza, P.; López-Farré, A.; de-Miguel-Diez, J.; Jiménez-García, R.; Albaladejo-Vicente, R. Trends and Predictors for the Uptake of Colon Cancer Screening Using the Fecal Occult Blood Test in Spain from 2011 to 2017. Int. J. Environ. Res. Public Health 2020, 17, 6222. [Google Scholar] [CrossRef] [PubMed]
  40. Wee, C.C.; McCarthy, E.P.; Davis, R.B.; Phillips, R.S. Screening for cervical and breast cancer: Is obesity an unrecognized barrier to preventive care? Ann. Intern. Med. 2000, 132, 697–704. [Google Scholar] [CrossRef]
  41. Cade, J.; O’Connell, S. Management of weight problems and obesity: Knowledge, attitudes and current practice of general practitioners. Br. J. Gen. Pract. 1991, 41, 147–150. [Google Scholar] [PubMed]
  42. Maruthur, N.M.; Bolen, S.D.; Brancati, F.L.; Clark, J.M. The association of obesity and cervical cancer screening: A systematic review and meta-analysis. Obesity 2009, 17, 375–381. [Google Scholar] [CrossRef] [PubMed]
  43. Sinnott, C.; McHugh, S.; Browne, J.; Bradley, C. GPs’ perspectives on the management of patients with multimorbidity: Systematic review and synthesis of qualitative research. BMJ Open 2013, 3, e003610. [Google Scholar] [CrossRef]
  44. Østbye, T.; Yarnall, K.S.; Krause, K.M.; Pollak, K.I.; Gradison, M.; Michener, J.L. Is there time for management of patients with chronic diseases in primary care? Ann. Fam. Med. 2005, 3, 209–214. [Google Scholar] [CrossRef]
  45. Streja, D.A.; Rabkin, S.W. Factors associated with implementation of preventive care measures in patients with diabetes mellitus. Arch. Intern. Med. 1999, 159, 294–302. [Google Scholar] [CrossRef]
  46. Cheung, A.; Stukel, T.A.; Alter, D.A.; Glazier, R.H.; Ling, V.; Wang, X.; Shah, B.R. Primary Care Physician Volume and Quality of Diabetes Care: A Population-Based Cohort Study. Ann. Intern. Med. 2017, 166, 240–247. [Google Scholar] [CrossRef]
  47. Redelmeier, D.A.; Tan, S.H.; Booth, G.L. The treatment of unrelated disorders in patients with chronic medical diseases. N. Engl. J. Med. 1998, 338, 1516–1520. [Google Scholar] [CrossRef]
  48. Lafata, J.E.; Martin, S.; Morlock, R.; Divine, G.; Xi, H. Provider type and the receipt of general and diabetes-related preventive health services among patients with diabetes. Med. Care 2001, 39, 491–499. [Google Scholar] [CrossRef]
Table 1. Distribution according to study variables of people with diabetes diagnosis included in the European Health Interview Surveys for Spain (EHISS) conducted in the years 2014 and 2020.
Table 1. Distribution according to study variables of people with diabetes diagnosis included in the European Health Interview Surveys for Spain (EHISS) conducted in the years 2014 and 2020.
VariableCategoriesEHISS 2014
(N = 941)
EHISS 2020
(N = 911)
p-Value
n%n%
GenderMale 53156.452157.20.741
Female41043.639042.8
Age (Years old)Mean (SD)57.7 (9.7)58.4 (9.1)0.143
Age groups (Years old)18–39576.1495.40.204
40–4911712.4879.5
50–59 27429.128030.7
60–6949352.449554.3
Education levelNo studies/primary14014.99910.90.009
Secondary70775.169476.2
High education9410.011813.0
Living with a partnerYes62266.157162.70.105
Self-rated healthFair/poor/very poor39742.242947.1<0.034
Very good/good54457.848252.9
COPDYes11812.511112.20.816
Cardiac ischemiaYes818.6758.20.771
StrokeYes373.9333.60.727
CancerYes656.9616.70.857
Mental diseaseYes21623.017419.10.042
High blood pressureYes51154.348553.20.646
Alcohol consumptionYes50854.043147.30.174
Active smokingYes23825.322825.00.896
Sedentary lifestyleYes40242.736940.50.379
Body mass index (kg/m2)<2518520.521023.80.037
25–29.936140.137442.4
≥3035539.429833.8
Mammography (<2 years)Yes26670.424466.80.301
Pap smear (<3 years)Yes21352.023861.00.010
FOBT (<2 years) totalYes10613.826233.8<0.001
FOBT (<2 years) menYes6314.419535.9<0.001
FOBT (<2 years) womenYes4313.16728.9<0.001
Table 2. Prevalence of Spain's resident population with and without diabetes who underwent screening for breast according to sociodemographic, clinical and lifestyle features.
Table 2. Prevalence of Spain's resident population with and without diabetes who underwent screening for breast according to sociodemographic, clinical and lifestyle features.
Mammography Last 2 Years
VariablesCategoriesNo DiabetesDiabetesBothp-Value
n%n%n%
Gender Male-------
Female54272.951068.6105270.80.068
Age groups
(years old) A,B,C
18–39 -------
40–49 4349.43135.67442.50.066
50–59 18579.717475.035977.40.222
60–69 31474.130571.961973.00.486
Education level No studies/primary4565.28764.913265.00.967
Secondary 40073.936869.076871.50.076
High education 9772.95572.415272.70.930
Living with a partner A,CNo34276.031270.765473.40.426
Yes19968.919865.839767.30.076
Self-rated health Fair/poor/very poor33673.417765.851370.60.551
Very good/good20672.333370.353971.00.031
COPD No49373.543068.992371.30.070
Yes4968.18067.212967.50.906
Cardiac ischemiaNo53473.347768.3101170.80.041
Yes857.13373.34169.50.251
Stroke No53873.349568.8103371.00.056
Yes444.41565.21959.40.282
Cancer B,CNo49572.245366.994869.60.035
Yes4782.55786.410484.60.550
Mental disease No42171.734567.976670.00.171
Yes12177.616570.228673.10.108
High blood pressure B,CNo38871.721263.360068.50.009
Yes15476.229873.045274.10.396
Alcohol consumption ANo28669.836968.165568.80.581
Yes25676.914070.439674.40.095
Active smoking No42972.541570.284471.30.404
Yes11374.89562.520868.60.026
Sedentary lifestyleNo34873.328571.663372.50.585
Yes19472.422565.241968.40.058
Body mass index (kg/m2)<2523872.610360.634168.50.006
25–29.918476.017771.436173.70.241
≥309573.120071.729572.10.770
EHISS201428074.126670.454672.20.146
202026271.824466.850669.30.086
A: Significant association for population without diabetes; B: Significant association for population with diabetes; C: Significant association for both. p-value represents comparison of frequencies between non-diabetes and diabetes populations.
Table 3. Prevalence of Spain’s resident population with and without diabetes who underwent screening for cervix cancer according to sociodemographic, clinical and lifestyle features.
Table 3. Prevalence of Spain’s resident population with and without diabetes who underwent screening for cervix cancer according to sociodemographic, clinical and lifestyle features.
Pap Smear Last 3 Years
VariablesCategoriesNo DiabetesDiabetesBothp-Value
n%n%n%
Gender Male-------
Female48961.145156.494058.80.054
Age groups
(years old) A,B,C
18–39 3866.74171.97969.30.542
40–49 6069.06574.712571.80.399
50–59 16269.815165.131367.50.276
60–69 22954.019445.842349.90.016
Education level A,B,CNo studies/primary2028.65439.47435.70.124
Secondary 35361.533458.268759.80.253
High education 11674.46370.817973.10.544
Living with a partner CNo30864.228058.858861.50.347
Yes17956.617152.935054.80.090
Self-rated health A,CFair/poor/very poor32463.917757.850161.60.817
Very good/good16556.327455.543955.80.085
COPD No44661.838056.482659.20.041
Yes4355.17156.311455.90.864
Cardiac ischemia A,CNo48561.742956.991459.40.055
Yes428.62247.82643.30.203
Stroke A,CNo48761.644156.892859.20.056
Yes222.21041.71236.40.301
Cancer No45060.641857.086858.80.167
Yes3968.43349.37258.10.031
Mental disease No39862.430354.370158.60.318
Yes9156.214861.223959.20.005
High blood pressure B,CNo36661.524463.761062.40.489
Yes12360.020749.633053.10.015
Alcohol consumption A,C No25257.031754.356955.50.383
Yes23766.213362.137064.70.327
Active smoking C No38160.034354.772457.40.057
Yes10865.510862.421663.90.562
Sedentary lifestyle A,B,CNo32864.225860.358662.40.218
Yes16155.719351.935453.60.328
Body mass index (kg/m2) A,B,C<2524567.112062.536565.50.275
25–29.915460.914755.930158.30.252
≥307251.816455.423654.30.481
EHISS B,C201423858.021352.045155.00.079
202025164.423861.048962.70.336
A: Significant association for population without diabetes; B: Significant association for population with diabetes; C: Significant association for both. p-value represents comparison of frequencies between non-diabetes and diabetes populations.
Table 4. Prevalence of Spain’s resident population with and without diabetes who underwent screening for colorectal cancer according to sociodemographic, clinical and lifestyle features.
Table 4. Prevalence of Spain’s resident population with and without diabetes who underwent screening for colorectal cancer according to sociodemographic, clinical and lifestyle features.
FOBT Last 2 Years
VariablesCategoriesNo DiabetesDiabetesBothp-Value
n%n%n%
Gender Male21223.922024.843224.40.658
Female13921.214822.628721.90.548
Age groups
(years old) A,C
50–59 10318.612121.822420.20.178
60–69 24825.124725.049525.10.959
Education level A,CNo studies/primary139.64119.05415.30.017
Secondary 27123.928925.056024.50.524
High education 6724.73822.210523.80.547
Living with a partner B,CNo23324.126025.849325.00.914
Yes11720.510820.322520.40.376
Self-rated healthFair/poor/very poor23322.615323.438622.90.642
Very good/good11823.121524.233323.80.710
COPD No32222.731923.764123.20.517
Yes2923.84924.97824.50.824
Cardiac ischemiaNo33222.433323.866523.10.378
Yes1931.73524.65426.70.303
Stroke ANo34422.735023.769423.20.534
Yes724.11827.72526.60.719
Cancer A,CNo31922.132923.164822.60.504
Yes3232.73932.57132.60.981
Mental disease No29922.528323.458222.90.600
Yes5224.28525.513725.00.724
High blood pressureNo23422.415023.838422.90.522
Yes11723.521823.933523.80.854
Alcohol consumptionNo12520.418222.530721.60.333
Yes22624.418625.441224.80.621
Active smoking A,C No28124.228223.956324.00.863
Yes6918.28623.815520.90.061
Sedentary lifestyle A,B,CNo25124.522925.748025.10.540
Yes10019.313921.323920.40.396
Body mass index (kg/m2)<2512723.68427.821125.10.177
25–29.915223.114723.529923.30.847
≥306020.912923.018922.30.489
EHISS A,B,C201410013.010613.820613.40.653
202025132.426233.851333.10.553
A: Significant association for population without diabetes; B: Significant association for population with diabetes; C: Significant association for both. p-value represents comparison of frequencies between non-diabetes and diabetes populations.
Table 5. Predictors of adherence to mammography screening in women participating in the European Health Interview Surveys (2014 and 2020) in Spain, according to the presence of diabetes.
Table 5. Predictors of adherence to mammography screening in women participating in the European Health Interview Surveys (2014 and 2020) in Spain, according to the presence of diabetes.
VariablesCategoriesNo Diabetes
OR (95% CI)
Diabetes
OR (95% CI)
Both
OR (95% CI)
Age groups (years old)40–49111
50–594.85 (2.81–8.38)5.26 (3.06–9.04)4.88 (3.33–7.15)
60–693.46 (2.12–5.64)4.08 (2.45–6.80)3.56 (2.50–5.06)
Living with a partnerNo1-1
Yes13.24 (1.33–132.01)-15.81 (1.73–144.25)
CancerNo-11
Yes-2.88 (1.38–6.01)2.31 (1.38–3.86)
High blood pressureNo-11
Yes-NSNS
Alcohol consumptionNo1--
Yes1.54 (1.10–2.18)--
DiabetesNo--1
Yes--0.75 (0.59–0.96)
EHISS 2014111
2020NSNSNS
Table 6. Predictors of adherence to Pap smear screening in women participating in the European Health Interview Surveys (2014 and 2020) in Spain, according to the presence of diabetes.
Table 6. Predictors of adherence to Pap smear screening in women participating in the European Health Interview Surveys (2014 and 2020) in Spain, according to the presence of diabetes.
VariablesCategoriesNo Diabetes
OR (95% CI)
Diabetes
OR (95% CI)
Both
OR (95% CI)
Age groups (years old)18–39111
40–49NSNSNS
50–59NSNSNS
60–69NSNS0.53 (0.34–0.83)
Education level No studies/primary111
Secondary 3.27 (1.85–5.77)1.55 (1.03–2.31)2.00 (1.44–2.77)
High education 4.99 (2.53–9.84)2.26 (1.23–4.15)3.20 (1.95–4.68)
Self-rated healthFair/poor/very poorNS-NS
Very good/good1-1
Living with a partnerNo-11
Yes-NSNS
Cardiac ischemiaNo1-1
YesNS-NS
StrokeNo1-1
YesNS-NS
High blood pressureNo-11
Yes-NSNS
Alcohol consumptionNo1-1
YesNS-NS
Active smoking No--1
Yes--NS
Sedentary lifestyleNo11 1
YesNSNS0.79 (0.66–0.95)
Body mass index (kg/m2)<25111
25–29.9NSNSNS
≥30NSNSNS
DiabetesNo--1
Yes--NS
EHISS 2014111
2020NS1.39 (1.03–1.86)1.28 (1.04–1.58)
Table 7. Predictors of adherence to FBOT screening in women participating in the European Health Interview Surveys (2014 and 2020) in Spain, according to the presence of diabetes.
Table 7. Predictors of adherence to FBOT screening in women participating in the European Health Interview Surveys (2014 and 2020) in Spain, according to the presence of diabetes.
VariablesCategoriesNo Diabetes
OR (95% CI)
Diabetes
OR (95% CI)
Both
OR (95% CI)
GenderMale111
FemaleNSNSNS
Age groups (years old)18–39---
40–49---
50–59111
60–691.43 (1.09–1.87)NS1.31 (1.08–1.58)
Education level No studies/primary1-1
Secondary 2.69 (1.47–4.92)-1.62 (1.18–2.22)
High education 2.49 (1.29–4.80)-NS
Living with a partnerNo-11
Yes-NSNS
StrokeNo1--
YesNS--
CancerNo1-1
Yes1.80 (1.13–2.86)-1.74 (1.27–2.38)
Active smoking No1-1
YesNS-NS
Sedentary lifestyleNo11 1
Yes0.75 (0.57–0.99)NS0.79 (0.66–0.95)
DiabetesNo--1
Yes--NS
EHISS 2014111
20203.29 (2.52–4.28)3.23 (2.50–4.17)3.24 (2.70–3.90)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zeng-Zhang, L.; de Miguel-Diez, J.; López-de-Andrés, A.; Jiménez-García, R.; Ji, Z.; Meizoso-Pita, O.; Sevillano-Collantes, C.; Zamorano-León, J.J. Adherence to Screening Tests for Gynaecological and Colorectal Cancer in Patients with Diabetes in Spain: A Population-Based Study (2014–2020). J. Clin. Med. 2024, 13, 3047. https://doi.org/10.3390/jcm13113047

AMA Style

Zeng-Zhang L, de Miguel-Diez J, López-de-Andrés A, Jiménez-García R, Ji Z, Meizoso-Pita O, Sevillano-Collantes C, Zamorano-León JJ. Adherence to Screening Tests for Gynaecological and Colorectal Cancer in Patients with Diabetes in Spain: A Population-Based Study (2014–2020). Journal of Clinical Medicine. 2024; 13(11):3047. https://doi.org/10.3390/jcm13113047

Chicago/Turabian Style

Zeng-Zhang, Luyi, Javier de Miguel-Diez, Ana López-de-Andrés, Rodrigo Jiménez-García, Zichen Ji, Olalla Meizoso-Pita, Cristina Sevillano-Collantes, and Jose J. Zamorano-León. 2024. "Adherence to Screening Tests for Gynaecological and Colorectal Cancer in Patients with Diabetes in Spain: A Population-Based Study (2014–2020)" Journal of Clinical Medicine 13, no. 11: 3047. https://doi.org/10.3390/jcm13113047

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop